New Indication: Invokana - MPR

New Indication: Invokana

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

Invokana is now approved to reduce the risk of end-stage renal disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes and diabetic nephropathy with albuminuria >300mg/day. Find out more with our slideshow, complete drug monograph, and downloadable PDF.